Abilify Wins Approval for Bipolar Disorder

Calms uncontrolled mania

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, Oct. 6, 2004 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Bristol-Myers Squibb's schizophrenia drug Abilify (aripiprazole) to treat the acute mania associated with bipolar disorder.

The drug had been tested on 516 bipolar patients, showing significant improvement of symptoms of uncontrolled mania, the company said in a statement. More than 2 million people in the United States have bipolar disorder, a brain condition that causes unusual shifts in a person's mood, energy, and ability to function.

To learn more about bipolar disorder, visit the National Institute of Mental Health.


Last Updated: